Trending Topics in Gastroenterology
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies...
Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine...
Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and...
Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and...
This multicenter randomized trial evaluated whether combining upadacitinib with vedolizumab during induction therapy could improve outcomes in moderate-to-severe ulcerative colitis. A total of 113 patients were randomized to...
Introduction: Ustekinumab is an established treatment for moderate-to-severe Crohn’s disease, but secondary loss of response remains a significant clinical challenge during long-term therapy. In routine practice, dose intensification...
Infliximab exerts its therapeutic effect within intestinal tissue, yet most therapeutic drug monitoring currently relies on serum concentrations. This study is the first to directly compare serum and...
This large prospective PURE study evaluated the relationship between ultraprocessed grain consumption and the future development of inflammatory bowel disease across 124,590 participants from 21 countries. Ultraprocessed grains...
Introduction: Inflammatory bowel disease (IBD) exhibits marked heterogeneity in disease behavior, progression, and treatment response. Identifying genetic markers associated with aggressive disease could facilitate earlier risk stratification and...
Introduction: Vedolizumab has become a widely used first-line advanced therapy for ulcerative colitis (UC) because of its favorable efficacy and safety profile. However, a substantial proportion of patients...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.